Q3 Earnings Forecast for Solid Biosciences Issued By Wedbush

Key Points

• Wedbush analysts have revised their Q3 2025 earnings estimates for Solid Biosciences, projecting a loss of ($0.38) per share, an improvement from their previous estimate of ($0.46).
• Solid Biosciences currently holds an "Outperform" rating from Wedbush, with a target price of $14.00 per share, while the average price target among analysts is $15.00.
• The company's stock performance shows a market cap of $480.46 million, with shares opening at $6.17 and a 1-year trading range between $2.41 and $10.37.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Wedbush increased their Q3 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a research note issued to investors on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.38) per share for the quarter, up from their prior estimate of ($0.46). Wedbush has a "Outperform" rating and a $14.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.50) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09.

SLDB has been the topic of a number of other reports. Citigroup assumed coverage on shares of Solid Biosciences in a research report on Thursday, June 26th. They set a "buy" rating and a $14.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Solid Biosciences in a research note on Tuesday, June 17th. Chardan Capital reissued a "buy" rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, August 14th. Wall Street Zen raised Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Piper Sandler dropped their price target on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat.com, Solid Biosciences currently has an average rating of "Buy" and an average price target of $15.00.

Solid Biosciences Stock Performance

SLDB traded down $0.2050 during mid-day trading on Friday, reaching $5.5950. 396,582 shares of the stock were exchanged, compared to its average volume of 1,919,238. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The stock has a market capitalization of $435.68 million, a PE ratio of -2.00 and a beta of 2.44. The company has a 50 day moving average price of $5.67 and a two-hundred day moving average price of $4.48.

Institutional Trading of Solid Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Bain Capital Life Sciences Investors LLC boosted its holdings in Solid Biosciences by 96.1% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares during the period. Siren L.L.C. raised its holdings in Solid Biosciences by 97.8% during the 1st quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock valued at $27,439,000 after acquiring an additional 3,666,864 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Solid Biosciences by 285.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after acquiring an additional 4,981,400 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Solid Biosciences by 1.8% in the fourth quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock worth $11,400,000 after acquiring an additional 50,000 shares during the period. Finally, Redmile Group LLC grew its position in shares of Solid Biosciences by 228.2% in the first quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock valued at $7,471,000 after purchasing an additional 1,403,925 shares in the last quarter. Institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.